Steinert clinical trials at UCSD
1 research study open to eligible people
Showing trials for
Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
open to eligible people ages 16 years and up
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
La Jolla, California and other locations
Last updated: